Seeking Alpha

Johnson & Johnson (JNJ) to acquire Omrix Biopharmaceuticals (OMRI) for $438M ($25/share), an...

Johnson & Johnson (JNJ) to acquire Omrix Biopharmaceuticals (OMRI) for $438M ($25/share), an 18% premium. OMRI's lead product is its fibrin blood-clotting pad, which controls surgical bleeding, and which it claims is superior to JNJ's Surgicel. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|